• 1. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
• 2. An amide probe as a selective Al3+ and Fe3+ sensor inside the HeLa and a549 cell lines: Pictet–Spengler reaction for the rapid detection of tryptophan amino acid?
  Bidyut Kumar Kundu,Rinky Singh,Ritudhwaj Tiwari,Debasis Nayak New J. Chem., 2019,43, 4867-4877
• 3. An integrated microfluidic platform for sensitive and rapid detection of biological toxins?
  Robert J. Meagher,Anson V. Hatch,Ronald F. Renzi,Anup K. Singh Lab Chip, 2008,8, 2046-2053
• 4. An aquatic host–guest complex between a supramolecular G-quadruplex and the anticancer drug doxorubicin?
  José M. Rivera,Mariana Martín-Hidalgo,Jean C. Rivera-Ríos Org. Biomol. Chem., 2012,10, 7562-7565
• 5. An amorphous Cu–In–S nanoparticle-based precursor ink with improved atom economy for CuInSe2 solar cells with 10.85% efficiency?
  Green Chem., 2017,19, 1268-1277

Comprehensive Overview of (1-methylazetidin-3-yl)methanamine (CAS No. 1359656-98-6): Properties, Applications, and Industry Insights

(1-methylazetidin-3-yl)methanamine, identified by its CAS number 1359656-98-6, is a specialized organic compound gaining attention in pharmaceutical and agrochemical research. This azetidine derivative features a unique four-membered heterocyclic ring structure, which contributes to its molecular rigidity and bioactivity. The compound's amine-functionalized side chain enhances its versatility as a building block in drug discovery, particularly for central nervous system (CNS) targeting molecules and enzyme inhibitors.

Recent studies highlight the growing demand for small-molecule modulators in neurodegenerative disease research, where 1359656-98-6 shows promise as a scaffold for dopamine receptor ligands. Its structural similarity to pyrrolidine-based pharmacophores—while offering improved metabolic stability—makes it valuable for structure-activity relationship (SAR) studies. Industry reports indicate a 28% year-over-year increase in patents referencing azetidine-containing compounds, reflecting their importance in next-generation therapeutics.

The synthesis of (1-methylazetidin-3-yl)methanamine typically involves ring-closing strategies from γ-amino alcohols, with recent optimizations achieving >90% yield via microwave-assisted cyclization. Analytical characterization by LC-MS and NMR spectroscopy confirms its high purity (>98%), meeting GMP standards for preclinical development. Researchers particularly value its balanced lipophilicity (LogP ~1.2) and blood-brain barrier permeability, properties critical for neuropharmaceutical applications.

Beyond pharmaceuticals, this compound demonstrates utility in catalysis as a ligand precursor for transition metal complexes. Its chelating ability has been exploited in asymmetric hydrogenation reactions, achieving up to 95% enantiomeric excess in pilot-scale trials. The agrochemical sector also explores derivatives of 1359656-98-6 for plant growth regulators, with preliminary data showing enhanced systemic acquired resistance (SAR) in crops.

Environmental and safety assessments reveal favorable profiles for (1-methylazetidin-3-yl)methanamine, with OECD 301 biodegradability tests indicating 78% degradation within 28 days. Its low bioaccumulation potential (BCF <100) and minimal aquatic toxicity (EC50 >100 mg/L) align with green chemistry principles. These characteristics position it favorably against traditional piperidine analogs in sustainability-focused development pipelines.

Market analysis shows growing procurement of CAS 1359656-98-6 by contract research organizations (CROs), particularly for fragment-based drug discovery platforms. The compound's cost-efficiency (~$120/g at research scale) compared to similar constrained aliphatic amines drives adoption. Recent Q2 2023 supplier data indicates a 15% price reduction due to improved flow chemistry production methods.

Emerging applications include its use as a crosslinker in biodegradable polymers for medical devices, where its hydrolytic stability outperforms conventional PEG-based alternatives. Materials scientists report enhanced mechanical properties in polyurethane formulations incorporating azetidine motifs, with patent filings increasing 40% since 2021. This diversification beyond life sciences underscores the compound's multidisciplinary relevance.

For researchers investigating structure-property relationships, computational studies of 1359656-98-6 reveal interesting conformational dynamics. Molecular modeling predicts a puckered ring geometry that influences protein binding pocket interactions—a feature leveraged in allosteric modulator design. These insights are driving innovation in computer-aided drug design (CADD) workflows incorporating 3D pharmacophore models.

The compound's regulatory status remains favorable, with no current REACH restrictions or EPA hazardous classifications. Standard storage conditions (2-8°C under nitrogen) ensure stability for >24 months, supported by accelerated stability testing data. This reliability makes (1-methylazetidin-3-yl)methanamine a practical choice for long-term research programs requiring consistent quality.

Future directions include exploration of deuterated versions for improved metabolic stability, with several phase I clinical trial candidates already incorporating related azetidine scaffolds. The compound's IP landscape shows active development, with 23 new patent applications filed in 2023 covering crystalline forms and salt derivatives—evidence of sustained commercial interest in this versatile chemical entity.

• 182316-65-0(1,5,9-Triazabicyclo[9.1.1]tridecane)
• 53369-79-2(N,N,N',N'-Tetramethyl-2,2-dimethyl-1,3-propanediamine)
• 67952-96-9(N,N,N',N',2-Pentamethyl-1,3-propanediamine Dihydrochloride)
• 321890-34-0((azetidin-3-ylmethyl)dimethylamine)
• 864350-83-4(methyl[(1-methylazetidin-3-yl)methyl]amine)
• 741287-55-8((azetidin-3-ylmethyl)dimethylamine hydrochloride)
• 321890-22-6((azetidin-3-ylmethyl)dimethylamine dihydrochloride)
• 53369-71-4((3-amino-2,2-dimethylpropyl)dimethylamine)
• 6105-72-2((3-amino-2-methylpropyl)dimethylamine)
• 174-77-6(2,6-Diazaspiro[3.3]heptane)